Type A Meeting Request submitted to FDA to Review Proposed Study Design for a Second Ph 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
“During the Type A meeting in April, FDA expressed its understanding of the need for additional therapies in CTCL and its willingness to work with Soligenix. FDA provided significant insights into its thoughts on a clinical study design allowing our team to prepare a comprehensive proposal expeditiously,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We certainly appreciate the FDA’s responsiveness and continued collaboration demonstrated by categorizing this meeting as a Type A meeting. The proposed protocol for the confirmatory study retains the key design aspects from the FLASH study while addressing as much of the FDA’s initial feedback as feasible. We look forward to having a productive meeting with the FDA and obtaining agreement on a pivotal study design that is highly executable as quickly as possible.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib